Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy

• Published in: Cancer Immunology, Immunotherapy : CII Immunotherapy : CII, 2024-07, Vol.73 (9), p.173, Article 173
• Main Authors: Zhang, Zongliang, Yang, Nian, Xu, Long, Lu, Huaqing, Chen, Yongdong, Wang, Zeng, Lu, Qizhong, Zhong, Kunhong, Zhu, Zhixiong, Wang, Guoqing, Li, Hexian, Zheng, Meijun, Zhou, Liangxue, Tong, Aiping
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antitumor activity; B7 antigen; Cancer Research; Cell culture; Cell Line, Tumor; Female; Glioblastoma - immunology; Glioblastoma - therapy; Herpes viruses; Herpesvirus 1, Human - immunology; Humans; Immunology; Immunotherapy; Immunotherapy, Adoptive - methods; Lymphocytes; Lymphocytes T; Medicine; Medicine & Public Health; Metastases; Mice; Oncology; Oncolysis; Oncolytic Virotherapy - methods; Oncolytic Viruses - genetics; Oncolytic Viruses - immunology; Receptors, Chimeric Antigen - immunology; Solid tumors; T-Lymphocytes - immunology; Tumors; Xenograft Model Antitumor Assays
• ISSN: 1432-0851; 0340-7004; 1432-0851
• DOI: 10.1007/s00262-024-03757-8

Recent studies have indicated that combining oncolytic viruses with CAR-T cells in therapy has shown superior anti-tumor effects, representing a promising approach. Nonetheless, the localized delivery method of intratumoral injection poses challenges for treating metastatic tumors or distal tumors that are difficult to reach. To address this obstacle, we employed HSV-1-infected CAR-T cells, which systemically delivery HSV into solid tumors. The biological function of CAR-T cells remained intact after loading them with HSV for a period of three days. In both immunocompromised and immunocompetent GBM orthotopic mouse models, B7-H3 CAR-T cells effectively delivered HSV to tumor lesions, resulting in enhanced T-cell infiltration and significantly prolonged survival in mice. We also employed a bilateral subcutaneous tumor model and observed that the group receiving intratumoral virus injection exhibited a significant reduction in tumor volume on the injected side, while the group receiving intravenous infusion of CAR-T cells carrying HSV displayed suppressed tumor growth on both sides. Hence, CAR-T HSV cells offer notable advantages in the systemic delivery of HSV to distant tumors. In conclusion, our findings emphasize the potential of CAR-T cells as carriers for HSV, presenting significant advantages for oncolytic virotherapy targeting distant tumors.